AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01369745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02861963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RVOT reconstruction by femoral allogenic vein valve conduit
Description: Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
Study NCT02861963 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic-to-pulmonary artery shunts
Description: Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side.
Study NCT03953521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intermittent Theta burst stimulation
Description: Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
Study NCT03953521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta burst stimulation
Description: Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
Study NCT02809950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral carbohydrate beverage
Description: oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
Study NCT02809950 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: NPO from midnight of the day before surgery
Study NCT04493372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic inhibition
Description: Bolus phenylephrine infusion using the Oxford technique will generate the need to inhibit sympathetic activity. Similarly, resting state Mayer waves will be assessed with regard to heart rate and blood pressure responses.
Study NCT04493372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of sympathetic activation
Description: Cold pressor test of the hand will be used to cause sympathetic activation. Valsalva's maneuver will assess the ability to buffer against blood pressure fall (phase II).
Study NCT04493372 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing of autonomic dysreflexia
Description: Cold pressor test of the foot and bladder pressor response (in individuals with SCI) will be tested.
Study NCT02754518 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entresto
Study NCT00943397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
Study NCT00943397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Usual Care
Description: Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
Study NCT04504578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contact lens assisted corneal cross linking
Description: 40 eyes of 30 patients underwent CACXL. The central 9 mm of corneal epithelium was abraded , Iso-tonic riboflavin 0.1% was applied every 2 minutes for 10 minutes on the debrided cornea. A disposable soft Contact lens without an ultraviolet filter (Soflens, Bausch \& Lomb) was placed in the inferior fornix during soaking of the stroma with riboflavin for 10 minutes. The contact lens was applied on the corneal surface and the cornea was exposed to ultraviolet-A irradiation at fluence of 3.0 mW/cm2 for 30 minutes The uncorrected (UDVA) and best corrected (BDVA) visual acuity, and maximum (K max) keratometric values, were assessed before, and after 9 months CXL. Endothelial cell count was assessed before and 3 months after CXL. Anterior segment OCT was done 1 month after CXL to evaluate the presence and depth of the corneal stromal demarcation line.
Study NCT03317717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
Study NCT03317717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
Study NCT03777280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peek framework RPD
Description: it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
Study NCT03777280 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chromium framework RPD
Description: standard framework device
Study NCT00460239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
Study NCT00460239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
Study NCT00460239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular; double blind; once per week
Study NCT04026230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: Capsules including 80 mg of atorvastatin
Study NCT04026230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Similar capsules as in the atorvastatin arm, but without the active ingredient
Study NCT01084902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: once daily
Study NCT01084902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide
Description: Two times daily
Study NCT00866957 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
Study NCT02285075 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: temocillin PK/PD in haemodialysis
Description: Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
Study NCT02627456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
Study NCT02627456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge Material
Description: PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
Study NCT02627456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBS and HSA Diluent
Description: The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
Study NCT02627456 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
Study NCT02627456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coartem
Description: Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
Study NCT02627456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
Study NCT02627456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASAQ
Description: ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage.
Study NCT02627456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASAQ
Description: ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage.
Study NCT03610334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Study NCT03610334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Study NCT03610334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours
Study NCT03610334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (15.0-50.0mg) oral capsule
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Study NCT03610334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral (15.0-50.0mg) capsule
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.
Study NCT02482883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
Study NCT02482883 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized \[active stimulation vs non-active (placebo) stimulation\], for an initial period of 10 days.
Study NCT01911754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
Study NCT00301457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg once daily oral dose
Study NCT04621032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polygraphy monitoring
Description: All patients with visceral obesity have been tested for Obstructive Sleep Apnea and heart rhythm disorders by usage of polygraphy and Holter-ECG monitoring.
Study NCT04621032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory tests
Description: Blood samples for sodium, potassium, calcium, magnesium concentration and fasting glyceamia assessment hae been taken from all patients with visceral obesity.
Study NCT02951026 — intervention group
Intervention type: OTHER
Intervention: Not applicable (no therapy is administered as part of this study)
Description: No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study.
Study NCT01535443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: Drug: Bromfenac Other names: PRO-155
Study NCT02875795 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automatic speech processing tool
Study NCT04252885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and Ritonavir Tablets
Description: As indicated in arm/group descriptions
Study NCT04252885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol
Description: As indicated in arm/group descriptions
Study NCT03064048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo-ASA
Description: Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
Study NCT03064048 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
Study NCT03212859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach2Move
Description: Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions.
Study NCT03212859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context.
Study NCT04642417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary fiber literacy
Description: education
Study NCT04642417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: routine care
Study NCT02816073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pan-retinal photocoagulation using pattern scanning laser
Description: Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
Study NCT02693262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS Mode on Biotronik CRT-D
Description: Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
Study NCT02693262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer Mode on Biotronik CRT-D
Description: Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
Study NCT03157076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)
Description: The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
Study NCT01073826 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sport
Study NCT01073826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sport
Study NCT01073826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Study NCT01073826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study NCT00563914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferroquine (SSR97193)
Description: associated with artesunate
Study NCT00563914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine
Description: associated with artesunate
Study NCT02826161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
Study NCT02826161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
Study NCT03895203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT03895203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study NCT02826161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
Study NCT04094779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual relation care
Description: When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
Study NCT04094779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual relation care
Description: When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
Study NCT04094779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flash activity breath of fresh air
Description: When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
Study NCT03638141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV
Study NCT03638141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Cohort A dose)
Description: Tremelimumab IV
Study NCT03638141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Cohort B dose)
Description: Tremelimumab IV
Study NCT03131726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: see arm description
Study NCT01407263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node template
Description: Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.